Radiometal-Labeled Chitosan Microspheres as Transarterial Radioembolization Agents against Hepatocellular Carcinoma

Hui Wen Chan, Yi Hsuan Lo, Deng Yuan Chang, Jia Je Li, Wen Yi Chang, Chih Hao Chen, Chih Hsien Chang, Chuan Lin Chen, Hsin Ell Wang, Ren-Shyan Liu, Chun-Yi Wu*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Transarterial radioembolization (TARE) is an emerging treatment for patients with unresectable hepatocellular carcinoma (HCC). This study successfully developed radiometal-labeled chitosan microspheres (111In/177Lu-DTPA-CMS) with a diameter of 36.5 ± 5.3 μm for TARE. The radiochemical yields of111In/177Lu-DTPA-CMS were greater than 90% with high radiochemical purities (>98%). Most of the111In/177Lu-DTPA-CMS were retained in the hepatoma and liver at 1 h after intraarterial (i.a.) administration. Except for liver accumulation, radioactivity in each normal organ was less than 1% of the injected radioactivity (%IA) at 72 h after injection. At 10 days after injection of177Lu-DTPA-CMS (18.6 ± 1.3 MBq), the size of the hepatoma was significantly reduced by around 81%, while that of the rats in the control group continued to grow. This study demonstrated the effectiveness of177Lu-DTPA-CMS in the treatment of N1-S1 hepatoma.111In/177Lu-DTPA-CMS have the potential to be a superior theranostic pair for the treatment of clinical hepatoma.

Original languageEnglish
Article number180
JournalGels
Volume8
Issue number3
DOIs
StatePublished - Mar 2022

Keywords

  • hepatocellular carcinoma (HCC)
  • radiolabeled chitosan microspheres (In/Lu-DTPA-CMS)
  • theranostics
  • transarterial radioembolization (TARE)

Fingerprint

Dive into the research topics of 'Radiometal-Labeled Chitosan Microspheres as Transarterial Radioembolization Agents against Hepatocellular Carcinoma'. Together they form a unique fingerprint.

Cite this